Phase III Randomized, Placebo-Controlled, Crossover Study of Soy Protein Isolate for Hereditary Hemorrhagic Telangiectasia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

1996-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

OBJECTIVES: I. Evaluate migraine prophylaxis with soy protein isolate in patients with hereditary hemorrhagic telangiectasia.

II. Assess whether soy protein isolate reduces the frequency and severity of epistaxis and gastrointestinal bleeding in these patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PROTOCOL OUTLINE: This is a randomized study. One group of patients is treated with soy protein isolate for 12 weeks. The control group receives a placebo for 12 weeks.

Patients cross to the alternate group following a 4-week washout.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hereditary Hemorrhagic Telangiectasia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

soy protein isolate

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Hereditary hemorrhagic telangiectasia (HHT) with 2 of the following:
* First-degree relative with HHT
* History of recurrent epistaxis or gastrointestinal bleeding
* Three or more skin telangiectasia
* Migraine headache meeting International Headache Society criteria 3 or more times a month for more than 1 year
* No pattern of daily headaches
* No severe head trauma
* No onset of headaches after 50 years of age
* At least 1 month since migraine prophylaxis
* At least 1 month since any of the following medications: Beta blockers; Calcium channel blockers; Divalproex sodium; Tricyclic antidepressants; Selective serotonin re-uptake inhibitors
* Concurrent regular treatment for migraine and gastrointestinal hemorrhage allowed
* Creatinine no greater than 2.5 g/dL
* No allergy to soy
* No pregnant women
* No women with intent to become pregnant

Minimum Eligible Age

15 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Joshua R. Korzenik

Role: STUDY_CHAIR

Yale University

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

YALESM-8191

Identifier Type: -

Identifier Source: secondary_id

199/11799